Lansoprazole NDC 82461-713

NDC codes

FDA NDC Directory

Product NDC (as listed)82461-713Labeler and product segments. Claims need a package NDC.

Product NDC at billing width82461-0713Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
82461-713-30	82461071330	30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (82461-713-30)Marketed from Jan 11, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Lansoprazole
Generic name (nonproprietary): lansoprazole
Active ingredients: Lansoprazole — 30 mg/1
Dosage form: Capsule, Delayed release
Route: Oral
Labeler: Medcore LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 207394
Marketing start: Jan 11, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Inhibition Gastric Acid Secretion (Physiologic effect)Proton Pump Inhibitors (Mechanism)
Identifiers: Product ID 82461-713_1d65f51d-0c4e-4344-8669-691f5223e4c5SPL ID 1d65f51d-0c4e-4344-8669-691f5223e4c5SPL set ID 18b4020f-d7e6-42f8-838d-2b5da152530eRxCUI 311277UNII 0K5C5T2QPGUPC 0382461713300
Pharmacologic class: Proton Pump Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N482461071330 followed by a unit qualifier and the quantity

Package 82461-0713-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 16, 2026.

Indications (excerpt from the label)

Lansoprazole delayed-release capsules is a proton pump inhibitor (PPI) indicated for the: Treatment of active duodenal ulcer in adults. ( 1.1 ) Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults. ( 1.2 ) Maintenance of healed duodenal ulcers in adults. ( 1.3 ) Treatment of active benign gastric ulcer in adults. ( 1.4 ) Healing of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults. ( 1.5 ) Risk reduction of NSAID-associated gastric ulcer in adults. ( 1.6 ) Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older. ( 1.7 ) Treatment of erosive esophagitis (EE) in adults a…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 207394

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 207394
Product	Strength	Form · route	Labeler	Product NDC
Lansoprazole	Lansoprazole 30 mg/1	Capsule, Delayed releaseOral	Asclemed USA, Inc.	76420-621
Lansoprazole	Lansoprazole 30 mg/1	Capsule, Delayed releaseOral	A-S Medication Solutions	50090-5180
Lansoprazole	Lansoprazole 15 mg/1	Capsule, Delayed releaseOral	Ascend Laboratories, LLC	67877-274
Lansoprazole	Lansoprazole 30 mg/1	Capsule, Delayed releaseOral	Ascend Laboratories, LLC	67877-275